Advances in Renal Denervation in the Treatment of Hypertension

Hypertension significantly increases the risk of cardiovascular events and it is associated with high rates of disability and mortality. Hypertension is a common cause of cardiovascular and cerebrovascular accidents, which severely affect patients’ quality of life and lifespan. Current treatment strategies for hypertension are based primarily on medication and lifestyle interventions. The renal sympathetic nervous system plays an important role in the pathogenesis of hypertension, and catheter-based renal denervation (RDN) has provided a new concept for the treatment of hypertension. In recent years, studies on RDN have been performed worldwide. This article reviews the latest preclinical research and clinical evidence for RDN.

[1]  G. Mancia,et al.  Cardiovascular Risk Reduction After Renal Denervation According to Time in Therapeutic Systolic Blood Pressure Range. , 2022, Journal of the American College of Cardiology.

[2]  Hang Liu,et al.  The intrarenal blood pressure modulation system is differentially altered after renal denervation guided by different intensities of blood pressure responses , 2022, Hypertension Research.

[3]  G. Mancia,et al.  Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry , 2022, European heart journal. Quality of care & clinical outcomes.

[4]  Manesh R. Patel,et al.  Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial , 2022, The Lancet.

[5]  J. Ge,et al.  Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trial , 2022, Journal of Cardiovascular Translational Research.

[6]  Hang Liu,et al.  Present Evidence of Determinants to Predict the Efficacy of Renal Denervation , 2022, International journal of hypertension.

[7]  Namrata Krishnan,et al.  Update on Renal Sympathetic Denervation for the Treatment of Hypertension , 2022, Current Cardiology Reports.

[8]  K. Kario,et al.  Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial , 2022, The Lancet.

[9]  S. Hiremath,et al.  Rethinking Resistant Hypertension , 2022, Journal of clinical medicine.

[10]  Yulong Xiong,et al.  Device-Based Sympathetic Nerve Regulation for Cardiovascular Diseases , 2021, Frontiers in Cardiovascular Medicine.

[11]  C. Kim,et al.  Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial , 2021, Hypertension Research.

[12]  J. Qian,et al.  Optimal Strategy for HIFU-Based Renal Sympathetic Denervation in Canines , 2021, Frontiers in Cardiovascular Medicine.

[13]  Hang Liu,et al.  Mapping Renal Innervations by Renal Nerve Stimulation and Characterizations of Blood Pressure Response Patterns , 2021, Journal of Cardiovascular Translational Research.

[14]  G. Mancia,et al.  Renal denervation in patients with versus without chronic kidney disease: results from the global SYMPLICITY Registry with follow-up data of 3 years. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  M. Uder,et al.  Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial , 2021, The Lancet.

[16]  F. Mahfoud,et al.  Device Therapy of Hypertension , 2021, Circulation research.

[17]  M. Böhm,et al.  The current status of renal denervation for the treatment of arterial hypertension. , 2021, Progress in cardiovascular diseases.

[18]  P. Gosse,et al.  12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. , 2020, JACC. Cardiovascular interventions.

[19]  Lawrence A Leiter,et al.  Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. , 2020, The Canadian journal of cardiology.

[20]  A. Kirtane,et al.  Device-based therapies for arterial hypertension , 2020, Nature Reviews Cardiology.

[21]  Manesh R. Patel,et al.  Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial , 2020, The Lancet.

[22]  A. Cremer,et al.  Clinic Versus Ambulatory Blood Pressure in Resistant Hypertension: Impact of Antihypertensive Medication Nonadherence: A Post Hoc Analysis the DENERHTN Study. , 2019, Hypertension.

[23]  Hang Liu,et al.  Selective renal denervation guided by renal nerve stimulation: mapping renal nerves for unmet clinical needs , 2019, Journal of Human Hypertension.

[24]  Bo Zhang,et al.  Selective Renal Denervation Guided by Renal Nerve Stimulation in Canine. , 2019, Hypertension.

[25]  K. Kario,et al.  Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence. , 2019, JACC. Cardiovascular interventions.

[26]  T. Lohmeier,et al.  Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[27]  A. Kirtane,et al.  Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. , 2019, Circulation.

[28]  G. Mancia,et al.  Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry , 2019, European heart journal.

[29]  H. Thiele,et al.  A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN) , 2019, Circulation.

[30]  M. Voskuil,et al.  Safety and performance of diagnostic electrical mapping of renal nerves in hypertensive patients. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[31]  P. Xiao,et al.  Blood pressure elevation response to radiofrequency energy delivery: one novel predictive marker to long-term success of renal denervation , 2018, Journal of hypertension.

[32]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[33]  Jackson T. Wright,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.

[34]  S. Pocock,et al.  Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial , 2018, The Lancet.

[35]  Neil Chapman,et al.  Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial , 2018, The Lancet.

[36]  M. Esler,et al.  Selective vs. Global Renal Denervation: a Case for Less Is More , 2018, Current Hypertension Reports.

[37]  R. Schmieder,et al.  Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension – WAVE IV , 2017, Journal of hypertension.

[38]  Neil Chapman,et al.  Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial , 2017, The Lancet.

[39]  E. Kholmovski,et al.  Effect of applied energy in renal sympathetic denervation with magnetic resonance guided focused ultrasound in a porcine model , 2017, Journal of therapeutic ultrasound.

[40]  Bing Huang,et al.  Impacts of Renal Sympathetic Activation on Atrial Fibrillation: The Potential Role of the Autonomic Cross Talk Between Kidney and Heart , 2017, Journal of the American Heart Association.

[41]  B. Zrenner,et al.  Renal Artery Vasodilation May Be An Indicator of Successful Sympathetic Nerve Damage During Renal Denervation Procedure , 2016, Scientific Reports.

[42]  P. Gosse,et al.  Adherence to Antihypertensive Treatment and the Blood Pressure–Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial , 2016, Circulation.

[43]  J. Staessen,et al.  Renal Nerve Stimulation–Induced Blood Pressure Changes Predict Ambulatory Blood Pressure Response After Renal Denervation , 2016, Hypertension.

[44]  P. Neužil,et al.  Externally Delivered Focused Ultrasound for Renal Denervation. , 2016, JACC. Cardiovascular interventions.

[45]  J. Staessen,et al.  Persistent Increase in Blood Pressure After Renal Nerve Stimulation in Accessory Renal Arteries After Sympathetic Renal Denervation , 2016, Hypertension.

[46]  P. Xiao,et al.  The effect of two different renal denervation strategies on blood pressure in resistant hypertension: Comparison of full‐length versus proximal renal artery ablation , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[47]  R. Schmieder,et al.  Non-invasive Renal Denervation: Update on External Ultrasound Approaches , 2016, Current Hypertension Reports.

[48]  P. Blankestijn,et al.  The morphological substrate for Renal Denervation: Nerve distribution patterns and parasympathetic nerves. A post-mortem histological study. , 2016, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.

[49]  E. Kholmovski,et al.  Renal sympathetic denervation using MR-guided high-intensity focused ultrasound in a porcine model , 2016, Journal of therapeutic ultrasound.

[50]  S. Pocock,et al.  The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. , 2016, American heart journal.

[51]  Que Zhu,et al.  Noninvasive Renal Denervation for Resistant Hypertension Using High-Intensity Focused Ultrasound , 2015, Hypertension.

[52]  B. Zrenner,et al.  Selective Proximal Renal Denervation Guided by Autonomic Responses Evoked via High-Frequency Stimulation in a Preclinical Canine Model , 2015, Circulation. Cardiovascular interventions.

[53]  P. Gosse,et al.  Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial , 2015, The Lancet.

[54]  Deepak L. Bhatt,et al.  Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. , 2015, European heart journal.

[55]  J. Staessen,et al.  Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study , 2014, Journal of Human Hypertension.

[56]  R. Virmani,et al.  Anatomic assessment of sympathetic peri-arterial renal nerves in man. , 2014, Journal of the American College of Cardiology.

[57]  Deepak L. Bhatt,et al.  Refining calcium test for diagnosis of medullary thyroid cancer: cutoffs, procedures and safety , 2014, The New England journal of medicine.

[58]  S. Inci,et al.  Assessment of effect of irbesartan and nebivolol on the left atrium volume and deformation in the patients with mild-moderate hypertension. , 2014, European review for medical and pharmacological sciences.

[59]  Que Zhu,et al.  Noninvasive renal sympathetic denervation by extracorporeal high-intensity focused ultrasound in a pre-clinical canine model. , 2013, Journal of the American College of Cardiology.

[60]  K. Iijima,et al.  Blood Pressure and Autonomic Responses to Electrical Stimulation of the Renal Arterial Nerves Before and After Ablation of the Renal Artery , 2013, Hypertension.

[61]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[62]  Krzysztof Bartus,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2009, The Lancet.